Treating Mooren's Ulcer - Squeezing Water From a Stone.
Aamir Husain1, Amna Saleem2, Zain Ali Zaidi3
1Opthalmology, Jinnah Medical and Dental College, Karachi, PAK.
Cureus
|January 28, 2021
Summary
Mooren's ulcer, a rare corneal disease, causes painful ulcers and vision loss. This case highlights a severe presentation despite extensive treatments, emphasizing the idiopathic nature and challenges in managing this condition.
Area of Science:
- Ophthalmology
- Immunology
Background:
- Mooren's ulcer is a rare, painful peripheral corneal ulcer of unknown autoimmune origin.
- It can lead to corneal opacity, degeneration, and irreversible vision loss if untreated.
Observation:
- A 60-year-old male presented with a classic, severe Mooren's ulcer in his right eye.
- The patient had a history of Mooren's ulcer in the left eye with complete vision loss.
- He experienced intense pain, redness, photophobia, and progressive vision decline.
Findings:
- The case presented as idiopathic, with no identifiable comorbid systemic conditions.
- Despite multiple treatments including tarsorrhaphy, amniotic membrane grafting, conjunctival flap, and scleral patch graft, the affected eye could not be permanently salvaged.
Implications:
- This case underscores the aggressive nature and poor prognosis of some Mooren's ulcer presentations.
- It highlights the limitations of current therapeutic interventions in preventing permanent vision loss.
- Further research into the idiopathic etiology and advanced treatment strategies for Mooren's ulcer is warranted.
More Related Videos
Related Concept Videos
Peptic Ulcer Disease IV: Management
235
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
235
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
969
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
969
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
739
Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
739
Peptic Ulcer Disease V: Surgical Management and Nursing Care
599
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
599
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
813
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
813
Peptic Ulcer Disease I: Introduction
473
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
473


